```
Summarize your explanation of the Bayesian sequential monitoring, Predictive Probability of Success, sample size determination, keep all the examples with numbers
```

### Bayesian sequential monitoring

Here is a summary of how these statistical tools work together to guide a drug like Innorna's through clinical trials:

1. Bayesian Sequential Monitoring (The "Real-Time" Update)

Instead of waiting until the end of a trial to look at the results, researchers use **Bayes' Theorem** to update their belief every time new patient data arrives.

- **The Math:** \(\text{Posterior} \propto \text{Prior} \times \text{Likelihood}\).
- **The Example:**
    - **Prior:** You are **60%** sure the drug works based on early lab tests.
    - **Likelihood:** You test **10 patients** and **8 succeed**. The math shows it’s highly unlikely for a bad drug to get 8/10.
    - **Posterior:** Your updated confidence jumps to **97%**.
- **The Correction:** If the next **5 patients all fail**, the math incorporates that "bad news" immediately, and your confidence might crash from **97% back down to ~9%**, signaling a potential trial stop.

2. Predictive Probability of Success (The "Forecaster")

While the Posterior looks at the _past_, **PPoS** looks at the _future_. It simulates the rest of the trial to see if finishing it is worth the money.

- **The Example:** You have **5 patients left** to enroll.
    - If the math shows you only need **1 more success** to win, your PPoS might be **99%** (Keep going!).
    - If you need **5 out of 5 successes** to win, the PPoS might be only **12%**.
- **Decision:** At 12%, you stop the trial for **futility** to save costs for the IPO.

3. Sample Size Determination (The "Insurance Policy")

In Phase III, you use Phase II data to calculate exactly how many patients you need to prove your drug is better than a placebo or a competitor. This depends on the **Effect Size** (the "drop" in uric acid).

- **Standard Deviation (Noise):** 1.5 mg/dL.
- **Scenario A (Large Drop):** Net difference of **2.0 mg/dL** \(\rightarrow \) needs only **50 patients** total.
- **Scenario B (Medium Drop):** Net difference of **1.0 mg/dL** \(\rightarrow \) needs **190 patients** total.
- **Scenario C (Small Drop):** Net difference of **0.5 mg/dL** \(\rightarrow \) needs **760 patients** total.

Summary

- **Monitoring** tells you if the drug is working _now_.
- **Predictive Probability** tells you if the trial will _finish_ successfully.
- **Sample Size** ensures the final trial is large enough to drown out _noise_ and satisfy regulators.



## Images attached below


![](file-20260505141954332.png)


![](file-20260505141954333.png)

![](file-20260505141954335.png)

![](file-20260505141954336.png)

![](file-20260505141954336%201.png)